About Conference

We invite participants from around the world to join us at the "12th Annual Congress on Pulmonary and Critical Care ," scheduled during November 28-29, 2024 in Paris, France. This year's Pulmonary Meet 2024 will focus on the theme "Groundbreaking Advances in Respiratory Medicine."

The goal of this conference is to exchange innovative ideas and recent developments in current research by bringing together leading global researchers, industry experts, scholars, decision-makers, and other professionals in pulmonology and critical care. Pulmonary Meet 2024 is set to be one of the most noteworthy events of the year.

Pulmonary Meet 2024 invites pulmonologists, respiratory care practitioners, and specialists in respiratory medicine from around the globe to explore the latest trends in screening, diagnosing, treating, and managing respiratory diseases. The conference will feature strategic sessions on a wide range of topics, including COPD, asthma, allergies, cystic fibrosis, pneumonia, tuberculosis, emphysema, lung cancer, complex chest infections, pulmonary fibrosis, sleep apnea, interstitial lung disease, lung nodules, chronic cough, influenza, mycobacterial infections, pediatric pulmonary conditions, bronchiectasis, and critical care. Additionally, the conference will address health care disciplines focused on optimizing cardiopulmonary function, health, and wellness.

Pulmonary Meet 2024 will feature distinguished keynote addresses, research presentations through both oral and poster sessions, and engaging networking opportunities. Attendees can also look forward to one-on-one meetings, exhibitor showcases, and interactive workshops.

Why to attend?

This event provides a unique opportunity to engage with leading experts in pulmonology and critical care from around the globe. It is a premier chance to connect with top professionals from research institutions, universities, clinics, and hospitals. Attendees can share data, conduct demonstrations, meet potential speakers, showcase new products, and gain recognition over these two days. The conference will feature world-renowned speakers, cutting-edge techniques, and the latest updates in the field, aiming to advance professional development and drive future discoveries. The primary goal is to inspire innovative treatment ideas that benefit pulmonologists across all specializations.

Target Audience:

• Pulmonologists
• Critical care professionals
• Pediatric pulmonologists
• Pulmonology Professors
• Pulmonology Nurses
• Critical care Hygienists
• Therapists
• Health Care Professionals
• Scientists & Researchers
• Academic Professionals
• Medical Students
• Manufacturing Medical Devices Companies

Sessions & Tracks

Track 01- Pulmonology

Pulmonology, also known as respiratory medicine, is a subspecialty of internal medicine focused on the health of the respiratory system, including the lungs, airways, and respiratory muscles. Pulmonologists diagnose and treat conditions that affect breathing and lung function.

Common Pulmonary Diseases and Conditions:

1. Asthma: A chronic inflammatory disease of the airways characterized by episodes of wheezing, shortness of breath, chest tightness, and coughing.
2. Chronic Obstructive Pulmonary Disease (COPD): A group of lung conditions, including chronic bronchitis and emphysema, that cause breathing difficulties due to airflow obstruction.
3. Lung Cancer: Malignancies originating in the lung tissue, which can be primary or metastatic.
4. Pneumonia: An infection of the lungs that causes inflammation and filling of the alveoli with fluid or pus, leading to cough, fever, and difficulty breathing.
5. Tuberculosis (TB): A bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially impacting other organs.

Pulmonologists work in various settings, including hospitals, outpatient clinics, and specialized care centers, often collaborating with other healthcare professionals to provide comprehensive care for patients with respiratory conditions.

Track 02 - Lung Cancer

Lung cancer remains one of the most common and deadly forms of cancer worldwide. There have been significant advancements and ongoing research in the field aimed at improving diagnosis, treatment, and patient outcomes. Lung cancer research is rapidly evolving, with numerous advancements in diagnosis, treatment, and personalized medicine. The integration of new technologies and a deeper understanding of the genetic and molecular landscape of lung cancer are paving the way for improved patient outcomes and survival rates.

Track 03 - Respiratory Disorders

Respiratory disorders encompass a wide range of conditions that affect the lungs and respiratory system. These disorders can be chronic or acute, and their management often requires a multidisciplinary approach. The field of respiratory medicine is rapidly evolving, with significant advancements in the understanding, diagnosis, and treatment of various respiratory disorders. The integration of new technologies, personalized medicine, and a focus on environmental health are driving improvements in patient outcomes and quality of life.

Track 04 – COPD

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by persistent airflow limitation and respiratory symptoms. It includes emphysema and chronic bronchitis. COPD is primarily caused by long-term exposure to harmful substances such as tobacco smoke, air pollution, and occupational dust and chemicals. COPD management is advancing through the development of combination inhalers, improved pulmonary rehabilitation programs, and innovative treatments for emphysema. Early diagnosis and personalized medicine are becoming increasingly important in improving patient outcomes.

Track 05- Respiratory Tract Infections

Respiratory tract infections (RTIs) encompass a variety of infections that affect the respiratory system, including the upper respiratory tract (e.g., common cold, sinusitis, laryngitis) and the lower respiratory tract (e.g., bronchitis, pneumonia). These infections can range from mild to severe and can be caused by viruses, bacteria, and other pathogens. Respiratory tract infections remain a significant public health challenge, but ongoing research and advancements in diagnostics, treatments, and preventive measures are improving outcomes. The lessons learned from the COVID-19 pandemic have accelerated progress in the field and highlighted the importance of global cooperation in combating respiratory infections.

Track 06 - Pulmonary Rehabilitation

Pulmonary rehabilitation is a comprehensive intervention designed to improve the physical and emotional well-being of people with chronic respiratory diseases. It includes exercise training, education, and behavioral changes aimed at improving the overall health and quality of life of patients. Pulmonary rehabilitation is a cornerstone in the management of chronic respiratory diseases, providing significant benefits in terms of symptom relief, exercise capacity, and quality of life. Advances in tele-rehabilitation and personalized care are enhancing its accessibility and effectiveness.

Track 07 - Pleural Diseases

Pleural diseases involve conditions affecting the pleura, the thin membranes lining the lungs and the chest cavity. These conditions can lead to significant respiratory issues and require careful management. Pleural diseases encompass a range of conditions requiring multidisciplinary management. Advances in minimally invasive techniques, biomarker research, and personalized medicine are improving diagnosis, treatment, and outcomes for patients with pleural diseases.

Track 08 - Lung transplantation

Lung transplantation is a surgical procedure where a diseased or failing lung is replaced with a healthy lung from a donor. It’s typically considered for patients with end-stage lung diseases, such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, cystic fibrosis, or severe pulmonary hypertension. Advancements in surgical techniques, immunosuppressive drugs, and postoperative care have significantly improved outcomes for lung transplant recipients.

Types of Lung Transplants:

• Single-Lung Transplant: One lung is replaced.
• Double-Lung Transplant: Both lungs are replaced.
• Heart-Lung Transplant: Both the heart and lungs are replaced, typically for patients with both severe heart and lung conditions.

Track 09 – Tuberculosis

Tuberculosis (TB) is an infectious disease primarily caused by the bacterium Mycobacterium tuberculosis. It usually affects the lungs but can also involve other parts of the body. TB spreads through airborne droplets when an infected person coughs or sneezes. TB remains a significant global health issue, with ongoing efforts to improve diagnosis, treatment, and prevention strategies.

Forms of TB:

• Latent TB Infection (LTBI): The bacteria are present in the body but inactive, causing no symptoms and not spreadable. People with LTBI have a risk of developing active TB in the future.
• Active TB Disease: The bacteria are active and multiplying, causing symptoms and being contagious.

Symptoms of Active TB:

• Persistent cough (sometimes with blood)
• Chest pain
• Weight loss
• Fatigue
• Night sweats
• Fever
• Loss of appetite

Track 10 - Cystic Fibrosis

Cystic fibrosis (CF) is a genetic disorder that affects the respiratory and digestive systems. It is caused by mutations in the CFTR gene, which leads to the production of thick, sticky mucus that can clog the airways and lead to various complications. Advancements in treatment, particularly with the development of CFTR modulators, have significantly improved the quality of life and life expectancy for individuals with CF. Ongoing research continues to focus on gene therapies and other novel treatments to address the root causes of the disease.

Track 11- Prevention and Control of Respiratory disease

Preventing and controlling respiratory diseases involves a combination of strategies aimed at reducing risk factors, improving early detection, and managing conditions effectively. Here are key approaches:

1. Vaccination:

• Influenza: Annual flu vaccines reduce the risk of flu-related respiratory complications.
• Pneumococcal Vaccine: Protects against pneumococcal infections that can cause pneumonia.
• BCG Vaccine: For tuberculosis, although its efficacy varies by region.

2. Smoking Cessation:

• Avoid Smoking: Smoking is a leading cause of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and lung cancer.
• Support Programs: Use of nicotine replacement therapy, counseling, and smoking cessation programs can be effective.

3. Environmental Controls:

• Air Quality: Reduce exposure to air pollutants by avoiding heavily polluted areas and using air purifiers indoors.
• Occupational Hazards: Implement safety measures in workplaces to minimize exposure to harmful dust, chemicals, or fumes.
• Avoid Secondhand Smoke: Reduce exposure to secondhand smoke to protect non-smokers, especially children.

4. Infection Control:

• Hand Hygiene: Regular handwashing helps prevent the spread of respiratory infections.
• Respiratory Etiquette: Covering coughs and sneezes with tissues or elbows, and disposing of tissues properly.
• Stay Home When Sick: Prevents the spread of infectious respiratory diseases to others.

Implementing these strategies can significantly reduce the incidence and impact of respiratory diseases, improving overall public health and individual well-being.

Track 12- Chronic Bronchitis

Chronic bronchitis is a type of chronic obstructive pulmonary disease (COPD) characterized by inflammation and irritation of the bronchial tubes (the airways that carry air to and from the lungs). It involves a persistent cough that produces mucus and is typically diagnosed based on symptoms lasting for at least three months over two consecutive years. Chronic bronchitis is a progressive condition, but with appropriate management and lifestyle changes, individuals can improve their symptoms and quality of life.

Track 13 – Asthma

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, which leads to difficulty breathing. It often involves episodic symptoms such as wheezing, shortness of breath, chest tightness, and coughing. Asthma can vary in severity and is influenced by a range of triggers.

Symptoms:

• Wheezing: A high-pitched whistling sound when breathing, especially during exhalation.
• Shortness of Breath: Difficulty breathing, often worse at night or early morning.
• Chest Tightness: A feeling of pressure or tightness in the chest.
• Coughing: Often worse at night or early morning, and can be dry or productive.

With appropriate treatment and management strategies, many people with asthma can achieve good control of their symptoms and lead active, healthy lives.

Track 14- Interstitial lung disease

Interstitial lung disease (ILD) is a group of disorders characterized by inflammation and scarring (fibrosis) of the lung tissue, particularly affecting the interstitium, which is the tissue and space around the alveoli (air sacs) in the lungs. This scarring can lead to a decrease in lung function and difficulty breathing.

Symptoms:

• Shortness of Breath
• Chronic Dry Cough
• Fatigue
• Weight Loss
• Clubbing of Fingers

Idiopathic Interstitial Pneumonias (IIPs) include Idiopathic Pulmonary Fibrosis (IPF), which is the most common type and involves progressive lung scarring with no known cause. Other IIPs include Nonspecific Interstitial Pneumonia (NSIP), characterized by varied lung injury patterns, and Desquamative Interstitial Pneumonia (DIP), often linked to smoking and marked by macrophage accumulation in the alveoli. Secondary Interstitial Lung Diseases (ILDs) can arise from connective tissue diseases like rheumatoid arthritis and lupus, drug-induced ILD from medications such as chemotherapeutics, occupational and environmental exposures to substances like asbestos and silica, infections (both viral and fungal), and radiation-induced ILD from cancer treatments.

Managing ILD requires a comprehensive approach, often involving a multidisciplinary team including pulmonologists, rheumatologists, and radiologists, to provide optimal care and improve the quality of life for affected individuals.

Track 15 - Pulmonary Hypertension

Pulmonary hypertension(PH) is a condition characterized by high blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. This elevated pressure makes it harder for the heart to pump blood through the lungs and can lead to various symptoms and complications. Pulmonary hypertension symptoms are Shortness of Breath, Fatigue , Chest Pain, Swelling, Dizziness or Fainting

Types of Pulmonary Hypertension:

• Pulmonary Arterial Hypertension (PAH)
• Secondary Pulmonary Hypertension

Pulmonary hypertension can arise from several underlying conditions. Autoimmune diseases, such as scleroderma and rheumatoid arthritis, may damage the lungs and contribute to the development of pulmonary hypertension. Congenital heart defects, which are structural abnormalities present from birth, can also lead to elevated pulmonary artery pressure. Additionally, pulmonary embolism, characterized by blood clots obstructing the pulmonary arteries, is a significant cause of this condition.

Track -16 Infectious Respiratory Diseases

Infectious respiratory diseases are illnesses caused by pathogens that affect the respiratory system, including the nose, throat, bronchi, and lungs. These diseases can range from mild to severe and may be caused by bacteria, viruses, fungi, or parasites. Infectious respiratory diseases encompass a variety of conditions affecting the upper and lower respiratory tracts. Upper respiratory infections (URIs) include the common cold, which is caused by viruses such as rhinoviruses and presents with symptoms like a runny nose, sore throat, cough, and congestion. Sinusitis, an inflammation or infection of the sinuses, often follows a cold or allergic reactions and is characterized by facial pain, nasal congestion, and headache. Pharyngitis involves inflammation of the pharynx, frequently due to viral infections like the common cold or bacterial infections such as streptococci.

Lower respiratory infections (LRIs) include bronchitis, which involves inflammation of the bronchial tubes and can be either acute, often due to viral infections, or chronic, typically caused by smoking or environmental irritants. Pneumonia is a more severe infection of the lungs caused by bacteria (e.g., Streptococcus pneumoniae), viruses (e.g., influenza virus), or fungi, and it presents with symptoms such as cough, fever, shortness of breath, and chest pain. Tuberculosis (TB) is a serious bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially involving other organs. It is marked by a chronic cough, weight loss, fever, and night sweats.

Specialized infections include COVID-19, caused by the SARS-CoV-2 virus, which ranges from mild respiratory issues to severe pneumonia and multi-organ involvement, and has had a profound global impact. Influenza (flu) is a viral infection known for causing seasonal epidemics, with symptoms like fever, cough, sore throat, body aches, and fatigue. Respiratory Syncytial Virus (RSV), common in infants and young children, can lead to bronchiolitis and pneumonia and also affect older adults.

Track 17 - Sleep-Related Respiratory Disorders

Sleep-related respiratory disorders encompass a range of conditions that affect breathing during sleep, impacting overall health and quality of life. These disorders can lead to fragmented sleep and other significant health issues.

Types:

• Obstructive Sleep Apnea (OSA)
• Central Sleep Apnea
• Complex Sleep Apnea Syndrome
• Sleep-Related Hypoventilation
• Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD)

Treatment for sleep-related respiratory disorders includes several approaches tailored to the specific type and severity of the condition. Continuous Positive Airway Pressure (CPAP) therapy is the primary treatment for obstructive sleep apnea, utilizing a machine that delivers a continuous stream of air to keep the airway open throughout the night. For complex sleep apnea and central sleep apnea, Adaptive Servo-Ventilation (ASV) and Bilevel Positive Airway Pressure (BiPAP) are used to assist with regulating breathing patterns. Lifestyle modifications can also play a significant role in managing symptoms, with weight loss, positional therapy, and avoiding alcohol or sedatives being particularly beneficial for obstructive sleep apnea. In cases where CPAP is not effective or for severe conditions, medical devices such as oral appliances may be used to maintain airway patency. Additionally, surgical interventions might be recommended to address anatomical abnormalities or reduce airway obstruction in select cases.

Track 18- Emphysema

Emphysema is a chronic lung condition that is part of chronic obstructive pulmonary disease (COPD). It involves the progressive destruction of the alveoli, the tiny air sacs in the lungs where gas exchange occurs. This damage reduces the surface area available for oxygen to enter the blood and carbon dioxide to be expelled, leading to breathing difficulties.

Emphysema is primarily caused by cigarette smoking, as the harmful chemicals in tobacco smoke damage lung tissue and lead to inflammation. Long-term exposure to environmental pollutants, such as air pollution, industrial fumes, and dust, can also contribute to the development of the disease. Additionally, a rare genetic condition known as alpha-1 antitrypsin deficiency can cause early-onset emphysema by impairing the lung's ability to protect itself from damage. The symptoms of emphysema include shortness of breath, especially during physical activity, due to the lungs' reduced capacity to exchange gases efficiently. Patients may also experience a chronic cough, often accompanied by sputum production, wheezing characterized by a high-pitched whistling sound during breathing, and fatigue resulting from decreased oxygen levels and the increased effort required to breathe.

Track 19 - Lung problems

Lung problems encompass a wide range of conditions that affect the respiratory system, impacting the ability to breathe and perform everyday activities. These issues can be acute or chronic, caused by infections, inflammation, structural abnormalities, or environmental factors.

Lung problems encompass a range of conditions affecting respiratory health. Respiratory infections include acute bronchitis, which involves inflammation of the bronchial tubes often caused by viral infections, leading to coughing, mucus production, and wheezing; pneumonia, an infection of the lungs that can be bacterial, viral, or fungal, resulting in symptoms such as cough, fever, chest pain, and difficulty breathing; and tuberculosis (TB), a serious bacterial infection primarily affecting the lungs, characterized by a persistent cough, weight loss, night sweats, and fever. Chronic respiratory diseases include chronic obstructive pulmonary disease (COPD), which comprises emphysema and chronic bronchitis, leading to long-term breathing difficulties, coughing, and mucus production, and asthma, a condition involving chronic inflammation and narrowing of the airways, causing wheezing, shortness of breath, chest tightness, and cough. Interstitial lung diseases (ILDs) include idiopathic pulmonary fibrosis (IPF), marked by progressive scarring of lung tissue and declining lung function, and sarcoidosis, an inflammatory disease causing granulomas in the lungs, resulting in cough, shortness of breath, and chest pain. Pulmonary hypertension involves elevated blood pressure in the pulmonary arteries, presenting symptoms such as shortness of breath, fatigue, and chest pain, and can be primary or secondary to other conditions like heart disease or chronic lung disease.

Track 20 – Pulmonary vascular disease

Pulmonary vascular disease refers to a range of conditions affecting the blood vessels in the lungs. These diseases can disrupt normal blood flow through the pulmonary arteries and veins, leading to significant health issues and impacting overall lung function. Pulmonary vascular diseases require careful management and treatment to improve symptoms, prevent complications, and enhance quality of life. Early diagnosis and appropriate therapy are crucial for managing these conditions effectively.

Pulmonary vascular disease encompasses various conditions affecting the blood vessels in the lungs. Pulmonary hypertension involves elevated blood pressure in the pulmonary arteries, potentially leading to right heart strain and failure, with causes ranging from primary genetic factors to secondary issues like heart disease or chronic lung conditions. Pulmonary embolism (PE) is a blockage in a pulmonary artery, typically due to blood clots from the legs, causing sudden shortness of breath, chest pain, and rapid heartbeat. Pulmonary arteriovenous malformations (PAVMs) are abnormal connections between arteries and veins in the lungs, which can reduce oxygen levels in the blood and lead to symptoms such as cyanosis and bleeding. Pulmonary vasculitis is inflammation of lung blood vessels, often seen in systemic conditions like Granulomatosis with Polyangiitis, presenting with cough, hemoptysis, and systemic symptoms. Pulmonary capillary hemangiomatosis is a rare condition characterized by capillary proliferation in the lungs, leading to pulmonary hypertension and impaired gas exchange, with symptoms including shortness of breath and cough. Each condition requires specific diagnostic and management approaches to address its unique challenges.

Market Analysis

The prevalence of Chronic Obstructive Pulmonary Disease (COPD) is increasing, with COPD being the third leading cause of death worldwide, responsible for 3.23 million deaths in 2019, according to the World Health Organization (WHO). This rise in COPD cases is expected to drive the demand for pulmonary and respiratory drug delivery systems, contributing to significant market growth.

The pulmonary/respiratory drug delivery market, valued at USD 53,018.64 million in 2021, is projected to reach USD 87,745.62 million by 2029, growing at a compound annual growth rate (CAGR) of 6.5% from 2022 to 2029. COPD is anticipated to be the largest application segment driving this market expansion due to favorable reimbursement policies and the high incidence and mortality associated with the disease.

The market report, prepared by the Data Bridge Market Research team, provides a comprehensive analysis including expert opinions, patient demographics, pipeline developments, pricing trends, and regulatory frameworks. Pulmonary and respiratory drug delivery systems are favored for their non-invasive nature, extensive absorption surface area, high blood circulation, and permeability, making them effective for treating respiratory tract conditions.

The pulmonary/respiratory drug delivery market analysis provides detailed insights into market size and trends across various segments, including country, product, canister type, application, distribution channel, and end user. The report encompasses several regions: North America (U.S., Canada, and Mexico), Europe (Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and the Rest of Europe), Asia-Pacific (APAC) (China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and the Rest of Asia-Pacific), Middle East and Africa (MEA) (Saudi Arabia, U.A.E, South Africa, Egypt, Israel, and the Rest of Middle East and Africa), and South America (Brazil, Argentina, and the Rest of South America). North America is the dominant market due to the presence of major key players, a growing demand for diagnostic devices such as Pulmonary Drug Delivery Systems (PDDS), increasing disposable income, and a high prevalence of respiratory conditions including asthma and chronic obstructive pulmonary disease (COPD).